Robert G. Mitchell, senior manager, contrast imaging solutions, explains how Bracco Diagnostics' acquisition of E-Z-EM further positions the company as a global leader in diagnostic imaging in radiology and cardiology. The merger allows for significant growth opportunities as E-Z-EM complements Bracco's comprehensive repertoire of diagnostic imaging agents. The synergies among both companies' product portfolios, complementary customer bases and technical expertise will strengthen Bracco Diagnostics' position in the evolving field of imaging informatics and patient management.
Related Content
News | Breast Imaging
March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...
March 13, 2026 
News | Radiology Business
March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...
March 13, 2026 
News | Enterprise Imaging
Mar. 9, 2026 — GE HealthCare recently announced that View, the viewer within the Genesis Radiology Workspace, has ...
March 12, 2026 
News | Lung Imaging
March 11, 2026 — Noah Medical has announced the publication of the MATCH 2 study in the international, peer-reviewed ...
March 12, 2026 
News | Computed Tomography (CT)
March 5, 2026 — At ECR 2026, Royal Philips introduced Rembra, its next-generation radiology CT system designed for the ...
March 09, 2026 
News | FDA
Mar. 9, 2026 — GE HealthCare's View, the powerful viewer within the Genesis Radiology Workspace, has received 510(k) ...
March 09, 2026 
Feature | Artificial Intelligence | Kyle Hardner
Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...
March 09, 2026 
News | HIMSS
March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...
March 06, 2026 
News | Radiology Business
March 5, 2026 — Cassling is now accepting applications for the 2026 Imaging for Impact Award, a national recognition ...
March 05, 2026 
March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...
March 04, 2026 © Copyright Wainscot Media. All Rights Reserved.
Subscribe Now